Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE008 (KOR) (Dr. Kim)
· consented 2023-07-17
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 42); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 42); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-07 (study day 46); relationship: N
severe
serious
assessed
2026-08-18
Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 66); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-18 (study day 87); relationship: N
severe
assessed
2026-08-18
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 91); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.